HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting
Date: December 6–9, 2025
Location: Orlando, Florida, USA
HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today presented new first-in-human data from its ongoing Phase 1 monotherapy study of HCB101, a 3.5th-generation SIRPα-Fc fusion protein, in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the 67th Annual Meeting of the American Society of Hematology (ASH) (ClinicalTrials.gov: NCT05892718).
The accepted abstract (#3299) includes a focused sub-analysis from HanchorBio’s ongoing multinational, open-label Phase 1 study evaluating HCB101 monotherapy across solid and hematologic malignancies, highlighting results from the R/R NHL cohort. HCB101 demonstrated a cytopenia-sparing safety profile along with early signals of clinical activity, representing a meaningful advancement in CD47–SIRPα therapeutic design.
Engineered using AI-assisted structural modeling, HCB101 was designed to enhance tumor selectivity while minimizing unnecessary red blood cell binding, aiming to expand the therapeutic window and improve the safety of CD47-based immune-modulating therapies.
About the ASH Annual Meeting
The American Society of Hematology (ASH) Annual Meeting is the world’s premier forum for scientific and clinical advancements in hematology. Each year, it brings together more than 27,000 hematologists and healthcare professionals from over 100 countries for high-level scientific exchange.
Founded in 1958, ASH is the world’s largest professional society dedicated to serving clinicians and scientists committed to the study and treatment of blood disorders, with a membership of over 18,000 individuals worldwide. ASH promotes global progress in the understanding, diagnosis, treatment, and prevention of disorders related to blood, bone marrow, the immune system, hemostasis, and the vascular system.
This year, the ASH Annual Meeting accepted more than 8,200 abstracts globally, maintaining its historically competitive ~28% rejection rate, underscoring its reputation as one of the most influential and rigorous medical congresses in hematology and oncology.
漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據
時間：2025 年 12 月 6–9 日
地點：美國佛羅里達州奧蘭多
HanchorBio Inc.（TPEx: 7827）是一家全球臨床階段的生物技術公司，致力於開發用於癌症與自身免疫疾病之次世代免疫療法。公司於 第 67 屆美國血液學會（ASH）年會 上，正式公布其 3.5 代新型 SIRPα-Fc 融合蛋白 HCB101 在復發／難治性非何杰金氏淋巴瘤（R/R NHL）患者中進行的 首次人體 I 期單藥治療研究最新臨床結果（ClinicalTrials.gov: NCT05892718）。
本次被 ASH 接受的摘要（編號 #3299），呈現 HanchorBio 正在進行的多國、多中心、開放標籤 Phase 1 研究之特定子分析，重點聚焦於 R/R NHL 受試者隊列。研究顯示，HCB101 展現 具細胞減少（cytopenia）風險更低的安全性特徵，以及 早期臨床活性證據。
HCB101 是以 AI 輔助蛋白結構建模進行工程化設計，使其具備強化的腫瘤靶向能力，並可最大程度降低對紅血球的非必要結合，提供更優化的治療窗口，代表 CD47–SIRPα 免疫檢查點調控療法的一項重要進展。
關於 ASH 年會
美國血液學會年會（ASH Annual Meeting）是全球血液學領域最具影響力的年度盛會，旨在促進血液學的研究、臨床照護與跨國學術交流。本屆年會預計吸引 來自 100 多個國家、超過 27,000 名 血液學家與醫療專業人員參與。
美國血液學會（ASH）成立於 1958 年，是全球規模最大的血液學專業組織，擁有超過 18,000 名 來自世界各地的會員。ASH 致力於推動血液、骨髓、免疫系統、止血與血管疾病之研究、診斷與治療，是全球血液學重要的教育與科學推動力量。
本屆 ASH 年會共收錄全球 超過 8,200 篇摘要，延續其約 28% 的歷史拒絕率，再度展現其作為全球血液與腫瘤領域最具競爭力與影響力的醫學會議地位。